General Information
Drug ID
DR00702
Drug Name
Telaprevir
Synonyms
(1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-6-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-octahydrocyclopenta[c]pyrrole-1-carboxamide; 402957-28-2; 655M5O3W0U; CHEBI:68595; CHEMBL231813; Incivek; Incivo; LY-570310; MP-424; S-Telaprevir; Telaprevir (VX-950); Telavic; UNII-655M5O3W0U; VRT-111950; VX 950; VX-950; VX-950(Telaprevir)
Drug Type
Small molecular drug
Indication Hepatitis C virus infection [ICD11:1E50.2, 1E51.1] Approved [1]
Structure
3D MOL 2D MOL
Formula
C36H53N7O6
Canonical SMILES
CCCC(C(=O)C(=O)NC1CC1)NC(=O)C2C3CCCC3CN2C(=O)C(C(C)(C)C)NC(=O)C(C4CCCCC4)NC(=O)C5=NC=CN=C5
InChI
InChI=1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30+/m0/s1
InChIKey
BBAWEDCPNXPBQM-GDEBMMAJSA-N
CAS Number
CAS 304853-42-7
Pharmaceutical Properties Molecular Weight 679.8 Topological Polar Surface Area 180
Heavy Atom Count 49 Rotatable Bond Count 14
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 8
XLogP
4.2
PubChem CID
3010818
PubChem SID
10039409 ,103533130 ,109693015 ,111630651 ,123105171 ,126578521 ,126666050 ,126727848 ,134223970 ,134340525 ,134340605 ,135692887 ,136920427 ,137188810 ,137273793 ,141479428 ,143498830 ,14839657 ,152234951 ,152258142 ,152344432 ,160645797 ,160646981 ,162011420 ,162197409 ,16347884 ,163884617 ,164193943 ,164765234 ,175266405 ,175426470 ,175427024 ,176250091 ,184812119 ,198992420 ,223366200 ,223385689 ,223669631 ,224452297 ,226544280 ,248618622 ,249810645 ,249821696 ,251916476 ,36059235 ,3723201 ,49684228 ,80491883 ,96025695 ,99455178
ChEBI ID
CHEBI:68595
TTD Drug ID
D0X9CH
DT(s) Transporting This Drug P-GP Transporter Info P-glycoprotein 1 Substrate [2]
References
1 Telaprevir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? Eur J Clin Pharmacol. 2014 Jul;70(7):775-89.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.